IP Library › Granted Patent US 9,579,297
Granted Patent B2
US 9,579,297 · App. 12/159,591 · Granted Feb 28, 2017

Pharmaceutical composition for application to nail

Inventors: Tomohiro Ishima (Yokohama, JP); Mamoru Naruse (Higashikagawa, JP); Hideo Kaneda (Kawachinagano, JP); Kazuo Kanai (Chuo-ku, JP); Takashi Sekine (Inashiki, JP); Shinichi Ota (Kashiwa, JP); Tomonari Yoshimura (Inashiki-gun, JP)
Assignee: TEIKOKU SEIYAKU CO., LTD.
A61K31/00A61F13/105A61K9/7061A61K31/4178A61K45/06A61F2013/00906
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,297
App. No.
12/159,591
Granted
Feb 28, 2017
Kind
B2
Abstract

Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly, treatments for nail tinea. The external preparation of this invention is a pharmaceutical composition for nail characterized by containing an antifungal drug, alkylpyrrolidone or a derivative thereof, and a crosslinking hydrogel.

Claims (9)

1. A pharmaceutical composition for nail consisting of an antifungal drug, alkylpyrrolidone or a derivative thereof, and a single crosslinking hydrogel,

wherein the antifungal drug is one or more selected from the group consisting of lanoconazole, clotrimazole, and bifonazole, and a content of the antifungal drug in the pharmaceutical composition is 1 to 5%,

the alkylpyrrolidone is N-methyl-2-pyrrolidone and a content of the alkylpyrrolidone in the pharmaceutical composition is 1 to 20%,

the single crosslinking hydrogel consists of 1 to 30% of a water-soluble crosslinking polymer, 1 to 50% of a polyvalent alcohol, 1 to 10% of an adhesion enhancer, 0.1 to 1% of a crosslinking agent, and 20 to 80% of water, and

the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of a pH adjusting agent, a thickener, a moisture adjuster, an absorption enhancer, and a surfactant.

2. The pharmaceutical composition for nail according to claim 1 , wherein the water-soluble crosslinking polymer is one or more selected from the group consisting of partially neutralized polyacrylate, polyacrylic acid, and carboxymcthyl cellulose sodium,

the polyvalent alcohol is one or more selected from the group consisting of glycols such as polyethyleneglycol and propyleneglycol, and glycerin,

the adhesion enhancer is one or more selected from the group consisting of polyvinyl alcohol, a carboxyvinyl polymer, and hydroxypropyl cellulose, and

the crosslinking agent is one or more selected from the group consisting of salts of a polyvalent aluminum, magnesium, or calcium compound, dried aluminum hydroxide gel, and glycinal.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2015
From: NIHON NOHYAKU CO., LTD.
To: TEIKOKU SEIYAKU CO., LTD.
Reel/Frame 036665/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2008
From: ISHIMA, TOMOHIRO; NARUSE, MAMORU; KANEDA, HIDEO; KANAI, KAZUO; SEKINE, TAKASHI; OTA, SHINICHI; YOSHIMURA, TOMONARI
To: TEIKOKU SEIYAKU CO., LTD.; NIHON NOHYAKU CO., LTD.; TSUMURA & CO.
Reel/Frame 021164/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2008
From: TSUMURA & CO.
To: TEIKOKU SEIYAKU CO., LTD.; NIHON NOHYAKU CO., LTD.
Reel/Frame 021164/0892 →
Priority Claims (1)
JP 2005-378441 · Dec 28, 2005 · national
Continuity (1)
Related Publication 20090202602A1 · Aug 13, 2009